Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Novartis Earlier Launched New $11B Share Buyback Program

Novartis Earlier Launched New $11B Share Buyback Program

-Reuters https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-launches-new-share-buyback-up-10-its-stock-2023-03-13/

byCharles Gross

March 13, 2023

1 minute read

-Reuters

https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-launches-new-share-buyback-up-10-its-stock-2023-03-13/

Why WeWork Stock Is Tumbling Wednesday

By Adam Eckert

August 9, 10:03 AM

WeWork Inc (NYSE: WE) shares are trading lower Wednesday after the company reported worse-than-expected financial results.

Methode Electronics, Brookfield Renewable Partners And Other Big Stocks Moving Lower On Tuesday

By Lisa Levin

June 13, 10:36 AM

U.S. stocks traded higher, with the Dow Jones rising around 100 points on Tuesday. Here are some big stocks recording losses in today’s session.

AVPT

FDA
News

Regeneron’s Dupixent Approved By FDA As First And Only Treatment Indicated For Prurigo Nodularis

By Michael Horton

September 28, 5:45 PM

Dupixent significantly reduced itch and skin lesions compared to placebo in direct-to-Phase 3 program consisting of two pivotal trials About 75,000 adults in the U.S. living with prurigo nodularis are most in need of

REGN

JP Morgan Maintains Overweight on Five Below, Raises Price Target to $184

By Benzinga Newsdesk

October 31, 9:11 AM

JP Morgan analyst Matthew Boss maintains Five Below (NASDAQ:FIVE) with a Overweight and raises the price target from $159 to $184.

FIVE

Novartis Earlier Launched New $11B Share Buyback Program

Related Posts

Why WeWork Stock Is Tumbling Wednesday

Methode Electronics, Brookfield Renewable Partners And Other Big Stocks Moving Lower On Tuesday

Regeneron’s Dupixent Approved By FDA As First And Only Treatment Indicated For Prurigo Nodularis

JP Morgan Maintains Overweight on Five Below, Raises Price Target to $184